直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Panel Discussion

China Pharma IP Summit

December 7-8, 2017

Shanghai, China

YIP Events

Finnegan attorneys Ningling Wang and Yieyie Yang will join the panel discussion "The U.S. Supreme Court Ruling on Amgen v. Sandoz and What Developers Need to Know" at the second annual China Pharma IP Summit, hosted by YIP Events. The program will take place at the DoubleTree by Hilton Pudong hotel in Shanghai, China. For more information, or to register, please see YIP Events' website.

Tags

Supreme Court of the United States (SCOTUS), Amgen Inc. v. Sandoz Inc.

Related Practices

Global IP Enforcement, Litigation, and Trials

Patent Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Biologics

Related Professionals

Ningling Wang
Partner
Shanghai
+86 21 6194 2005
Email
Yieyie Yang, Ph.D.
Partner
Washington, DC
+1 202 216 5170
Email

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP